Information Provided By: 
Fly News Breaks for April 27, 2018
ALKS
Apr 27, 2018 | 09:23 EDT
Goldman Sachs analyst Terence Flynn says Alkermes yesterday reported a Q1 beat with a "number of important catalysts ahead." To reflect the Q1 trends and guidance, the analyst raised his price target for the shares to $46 from $44. He keeps a Neutral rating on Alkermes and expects a number of late-stage pipeline catalysts in the second half of 2018, including the FDA advisory panel for depression drug ALKS 5461 and the Phase schizophrenia data for ALKS 3831.
News For ALKS From the Last 2 Days
